
Introduction: Cancer therapy has evolved from conventional cytotoxic agents to targeted therapies, immunotherapy, natural product-derived medicines, and precision oncology; however, tumour heterogeneity, therapeutic resistance, toxicity, and interpatient variability in treatment response remain major challenges. This review provides a unique integration of cancer biology, plant-derived anticancer scaffolds, structure-activity relationship (SAR) analysis, and artificial intelligence (AI)-assisted drug discovery in a single mechanism-to-molecule framework. Methods: A narrative review was conducted using peer-reviewed research articles, reviews, and authoritative scientific reports addressing cancer pathogenesis, therapeutic targets, anticancer agents, immunotherapy, medicinal plants, natural products, SAR, and AI-assisted drug discovery. Literature identification, screening, data collection, analysis, and interpretation were performed by the sole author. Evidence was qualitatively synthesised according to mechanistic relevance, pharmacological significance, structural determinants, therapeutic potential, and translational limitations. Results: Traditional cytotoxic medicines remain therapeutically important, although they are limited by systemic toxicity and the emergence of drug resistance. Targeted therapies and immunotherapies can increase therapeutic selectivity by targeting specific biological targets or immunological pathways, but their efficacy can be hampered by tumour heterogeneity, the need for predictive biomarkers, immune escape, and adaptive resistance. Natural products have translational utility, as exemplified by plant-derived scaffolds such as vinca alkaloids, taxanes, and epipodophyllotoxin derivatives. SAR-guided optimisation can improve potency and selectivity, whereas AI-assisted techniques support molecular prioritisation, property prediction, and lead optimisation. However, prediction performance still depends on data quality, model resilience, and experimental validation. Discussion: Integrating biological mechanisms, chemical structure–activity relationships, and computational predictions may improve the efficiency of anticancer drug discovery and development. However, reproducibility, model interpretability, and translation remain key challenges. Conclusion: Future advances will depend on standardised natural-product characterisation, mechanistic SAR, empirically verified AI models, biomarker-driven patient selection, and prospective clinical evaluation. Integrating multi-omics, structural biology, and generative artificial intelligence may facilitate personalised lead optimisation and accelerate the translation of promising candidates into clinically relevant medicines.
Introduction: Transcription of RNA from DNA-an essential step for gene expression and cellular function-is carried out by polymerases, which are essential enzymes. Unchecked cell proliferation, aberrant gene activity, and metastasis are all consequences of poor control of these enzymes in cancer. This review examines the causes of RNA polymerase dysregulation in cancer, assesses the therapeutic potential of transcription inhibitors, and talks about the difficulties encountered in their clinical development. Methods: The article reviews techniques for evaluating RNA polymerase inhibitors and examines research on RNA polymerase deficits in cancer. Drug selectivity, resistance mechanisms, toxicity to normal cells, and preclinical data supporting clinical usage are important considerations. Results: Tumor suppressor genes can be suppressed, and oncogene activity can be increased by elevated or overactivated RNA polymerases, which can accelerate the development of cancer. By specifically eliminating cancer cells and stopping oncogenic transcription, RNA polymerase inhibitors have demonstrated encouraging preclinical outcomes. Discussion: RNA polymerases are appealing therapeutic targets since malignancies rely significantly on transcription. Clinical effectiveness depends on increasing medication selectivity, reducing off-target effects, and overcoming resistance. Combining several inhibitors might increase efficacy. Conclusion: In conclusion, RNA polymerase targeting presents a viable strategy for cancer treatment. To optimize advantages, future research should focus on enhancing inhibitor selectivity, lowering toxicity, and creating combination therapies.
Abstract: Lung cancer (LC) remains an important worldwide health concern, requiring continuous improvements in both diagnosis and treatment. Recent advancements in lung cancer treatment are highlighted in this review, including the application of molecular biomarkers and nano-biosensors for early detection and tailored treatment. The results for nonsmall cell lung cancer (NSCLC) patients have significantly improved due to advancements in immunotherapies and targeted medications, particularly immune checkpoint inhibitors (ICIs). These days, ICIs are employed as first-line therapy for advanced cases as well as after surgery and chemoradiation. Finding trustworthy prognostic biomarkers is still crucial, though. The study also covers innovative surgical procedures such as VATS, RATS, laser surgery, ENB, RFA, MWA, and hybrid approaches. The growing significance of tumour-specific vaccinations is also examined, particularly when used in conjunction with ICIs. The emerging role of tumourspecific vaccines, especially in combination with ICIs, is explored. Overall, the paper provides a comprehensive overview of modern lung cancer therapy strategies, focusing on precision medicine.
Introduction: Oncolytic Virotherapy (OVT) is an emerging area of cancer immunotherapy that has shown promise as a therapeutic agent, leveraging genetically engineered replication- competent viruses that kill cancer cells without harming normal cells. HSV-1 (T-VEC), vaccinia, and adenoviruses. Immuno-Oncology Oncol Ther 2017; Monkey 7: 118 (HSV-1 (T-VEC), vaccinia, and adenoviruses also target tumor-specific dysregulations in pathways such as p53, Rb, IFN/PKR, and RAS-MAPK to induce cytolysis and immune activation). Methods: The keywords used for the literature review were strategic and included oncolytic virotherapy, tumor-specific lysis, immunogenic cell death, viral gene deletions, immune checkpoint synergy, and advanced delivery platforms. Articles in Scopus, PubMed, ScienceDirect, and Google Scholar were retrieved that were relevant for this purpose. Only recent, peer-reviewed publications published in English were included to ensure the quality, consistency, and reliability of the review. Results: These immunostimulatory cues convert the immunologically cold tumors into hot, T-cell-inflamed lesions. Improved immune infiltration is achieved through vascular-targeting (e.g., VSV, HSV-1716) and matrix-modifying effects. Newcastle disease virus, coxsackievirus, measles, poliovirus, and Maraba virus all expand the therapeutic arsenal, namely addressing preexisting immunity and intratumoral spread. New delivery platforms, such as mesenchymal stem cells, CAR-T cells, and biomineral-coated vesicles, are expected to enhance systemic circulation and targeting of metastatic sites. Discussion: There is synergistic antitumor activity when immune checkpoint blockade and adoptive T-cell therapy are combined with chemotherapy. However, there are still obstacles, such as antiviral clearance, stromal barriers, and the lack of biomarkers for predictive response. Conclusion: OVT is rapidly transitioning into a mainstream immuno-oncology platform through iterative engineering, effective innovative carriers, and rational multimodal regimens that provide sustained and systemic cancer control.
Abstract: Treosulfan is a bifunctional alkylating agent that has become increasingly clinically relevant in oncology and hematopoietic stem cell transplantation (HSCT) for its myeloablative, immunosuppressive, and antitumor effects. Treosulfan has been developed initially for the treatment of solid tumors such as ovarian carcinoma. It has shown therapeutic activity in both monotherapy and combination therapy settings, and has a favourable tolerability profile. It is used more commonly in HSCT and has been shown to have lower non-haematological toxicity than some traditional alkylating agents, especially in paediatric and elderly/high-risk patients who require myeloablative conditioning before HSCT. This review will summarise the pharmacological characteristics, mechanisms of action, clinical applications, pharmacokinetic considerations, and emerging therapeutic perspectives of treosulfan, with a special focus on oncology and HSCT. Treosulfan inhibits these effects via active metabolites, such as epoxides that cause DNA cross-linking and cell damage, via apoptosis, and through immunosuppressive properties that are important for transplantation conditioning. Clinical evidence supports its well-documented use in ovarian cancer and HSCT, while there is limited to preliminary evidence for several other cancers. Combination treatment strategies, formulation considerations, pharmacokinetic variability, and TDM are also discussed. Although encouraging clinical results have been achieved, there are issues with dose optimization, inter-patient pharmacokinetic variability, and the absence of longterm comparative clinical data. More prospective studies are required to establish standard dosing strategies, assess for long-term safety, and investigate biomarker-driven treatment strategies for clinical application.